First, our 32-gene signature is specific is to Treg-enriched patient tumor samples as determined by the previously described gene set enrichment analysis (GSEA) methods.17 In addition, although the variability of the 32 genes was strongly associated with patient survival and the well-characterized favorable immune determinants of the tumor in this study (e.g., CD8+ T cell, PRF1 and CD8A/B), it is important to be aware of the possibility that tumor heterogeneity may still at least partly influence the variability of gene transcript abundance. The gene discussed is PRF1; the disease is neoplasm.